Phenotype expression of human bone cells cultured on implant substrates
β Scribed by P. Locci; E. Becchetti; M. Pugliese; L. Rossi; S. Belcastro; M. Calvitti; G. Pietrarelli; N. Staffolani
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 204 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0263-6484
No coin nor oath required. For personal study only.
β¦ Synopsis
Bone cells derived from the human jaw were cultured on titanium, titanium coated with hydroxyapatite (THA) or with plasma spray (TPS) to study the behaviour of the cells anchored to implant substrates. Bone cells were cultured in MEM with the addition of [ 3 H]-thymidine to evaluate cellular proliferation, and [ 3 H]-glucosamine to evaluate GAG synthesis and accumulation in the extra-cellular matrix (ECM). Moreover, to study the degradation of GAG bone cells were cultured in the presence of NH 4 Cl, an amine known to inhibit lysosomal activity. Our results show that TPS is the substrate that favours both cellular proliferation and the accumulation of GAG in the ECM.
π SIMILAR VOLUMES
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is known to induce orthotopic and ectopic bone formation in vivo. Several in vitro studies using rat or mouse clonal cell lines have shown that rhBMP-2 may be involved in the differentiation of osteoblasts from osteoblast precursor cells or st
In the search for methods to improve the biocompatibility of prosthetic materials, attention has recently been directed toward the potential use of surface chemical modification and its influence on cellular behavior. This in vitro study investigates the effect of surface chemistry modification of b
The quantitative measurement of the expression of both cytoplasmic and surface CD63 antigen by human mast cells from both normal and pathological bone marrow samples was studied by use of flow cytometry. Our major goal was to analyze whether in vivo CD63 expression by human bone marrow mast cells co
Signal transduction initiated by TGFb1 and OP-1 was studied in MG63 human osteosarcoma cells and in normal human bone cells (HBCs) in the presence of inhibitors of signal transduction events, using insulinlike growth factor binding protein-3 (IGFBP-3) production as an end point. Treatment of serum-f